Modern strategies for etiotropic therapy and prevention of respiratory syncytial virus infection

Read full text Summarise with VIRAT
Authors: Mikhail M. Mirolaev, O. Burgasova, Кружкова Ирина Сергеевна, Elena I. Burtseva, Anatoly K. Tokmalaev
Cited by: 0
References: 45

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Respiratory syncytial virus remains one of the leading causes of lower respiratory tract infections worldwide and poses a serious threat to young children and older adults. This review aimed to analyze current strategies for the treatment and prevention of respiratory syncytial virus infection that have emerged as a result of fundamental advances in viral structural biology. The article reviews up-to-date epidemiological data, including changes in seasonality observed after the pandemic, as well as challenges in clinical diagnosis. It discusses evolution of passive immunoprophylaxis, and presents the results of studies evaluating the efficacy of novel recombinant vaccines for active immunization. Particular attention is paid to the assessment of promising agents for etiotropic therapy. The available evidence indicates that the introduction of new preventive and therapeutic interventions makes it possible to shift respiratory syncytial virus infection into the category of manageable diseases. An important future task is the establishment of continuous molecular epidemiological surveillance to monitor the potential development of viral resistance to existing therapeutic and preventive agents.

Fields of Study & Subjects

Respiratory viral infections research Virology and Viral Diseases SARS-CoV-2 and COVID-19 Research

Publication details

Journal / source
Epidemiology and Infectious Diseases
Volume
31
Issue
1
Pages
41–50
Publication date
17 February 2026
Language
EN